Involvement of HIF-1α activation in the doxorubicin resistance of human osteosarcoma cells

Roncuzzi,Laura; Pancotti,Fabia; Baldini,Nicola

doi:10.3892/or.2014.3181

Involvement of HIF-1α activation in the doxorubicin resistance of human osteosarcoma cells

Authors:
- Laura Roncuzzi
- Fabia Pancotti
- Nicola Baldini
View Affiliations

Affiliations: Laboratory for Orthopaedic Pathophysiology and Regenerative Medicine, Istituto Ortopedico Rizzoli, I-40136 Bologna, Italy
Published online on: May 15, 2014 https://doi.org/10.3892/or.2014.3181
Pages: 389-394

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Osteosarcoma is the most common primary bone cancer in children and adolescents. Despite aggressive treatment regimens, survival outcomes remain unsatisfactory, particularly in patients with metastatic and/or recurrent disease. Unfortunately, treatment failure is commonly due to the development of chemoresistance, for which the underlying molecular mechanisms remain unclear. The aim of the present study was to investigate the role of hypoxia-inducible factor 1α (HIF‑1α) and its signalling pathways as mediators of drug-resistance in human osteosarcoma. Toward this aim, we established two osteosarcoma cell lines selected for resistance to doxorubicin, a drug of choice in the treatment of this tumour. Our results showed that the multidrug resistance (MDR) phenotype was also mediated by HIF-1α, the most important regulator of cell adaptation to hypoxia. Our data showed that this transcription factor promoted the outward transport of intracellular doxorubicin by activating the P-glycoprotein (P-gp) expression in osteosarcoma cells maintained in normoxic conditions. In addition, it hindered doxorubicin-induced apoptosis by regulating the expression of c-Myc and p21. Finally, we observed that the doxorubicin-resistant cells maintained for 2 months of continuous culture in a drug-free medium, lost their drug-resistance and this effect was associated with the absence of HIF-1α expression. The emerging role of HIF-1α in osteosarcoma biology indicates its use as a valuable therapeutic target.

View Figures

View References

1	Heare T, Hensley MA and Dell’Orfano S: Bone tumors: osteosarcoma and Ewing’s sarcoma. Curr Opin Pediatr. 21:365–372. 2009.
2	Mankin HJ, Hornicek FJ, Rosenberg AE, Harmon DC and Gebhardt MC: Survival data for 648 patients with osteosarcoma treated at one institution. Clin Orthop Relat Res. 429:286–291. 2004. View Article : Google Scholar : PubMed/NCBI
3	Bacci G, Briccoli A, Rocca M, Ferrari S, Donati D, Longhi A, Bertoni F, Bacchini P, Giacomini S, Forni C, Manfrini M and Galletti S: Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. Ann Oncol. 14:1126–1134. 2003. View Article : Google Scholar
4	Lewis IJ, Nooij MA, Whelan J, Sydes MR, Grimer R, Hogendoorn PC, Memon MA, Weeden S, Uscinska BM, van Glabbeke M, Kirkpatrick A, Hauben EI and Craft AW: Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst. 99:112–128. 2007. View Article : Google Scholar
5	Baldini N, Scotlandi K, Barbanti-Bròdano G, Manara MC, Maurici D, Bacci G, Bertoni F, Picci P, Sottili S, Campanacci M and Serra M: Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med. 333:1380–1385. 1995. View Article : Google Scholar : PubMed/NCBI
6	Bielack SS, Carrle D, Hardes J, Schuck and Paulussen M: Bone tumors in adolescents and young adults. Curr Treat Options Oncol. 9:67–80. 2008. View Article : Google Scholar : PubMed/NCBI
7	Gottesman MM, Fojo T and Bates SE: Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2:48–58. 2002. View Article : Google Scholar : PubMed/NCBI
8	Borst P and Elferink RO: Mammalian ABC transporters in health and disease. Annu Rev Biochem. 71:537–592. 2002. View Article : Google Scholar : PubMed/NCBI
9	Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE and Gottesman MM: P-glycoprotein: from genomics to mechanism. Oncogene. 22:7468–7485. 2003. View Article : Google Scholar : PubMed/NCBI
10	Baldini N, Scotlandi K, Serra M, Picci P, Bacci G, Sottili S and Campanacci M: P-glycoprotein expression in osteosarcoma: a basis for risk-adapted adjuvant chemotherapy. J Orthop Res. 17:629–632. 1999. View Article : Google Scholar : PubMed/NCBI
11	Harguindey S, Orive G, Luis Pedraz J, Paradiso A and Reshkin SJ: The role of pH dynamics and the Na⁺/H⁺antiporter in the etiopathogenesis and treatment of cancer. Two faces of the same coin - one single nature. Biochim Biophys Acta. 1756:1–24. 2005.PubMed/NCBI
12	Shicang Y, Guijun H, Guisheng Q, Yuying L, Guoming W and Ruiling G: Efficacy of chemotherapeutic agents under hypoxic conditions in pulmonary adenocarcinoma multidrug resistant cell line. J Chemother. 19:203–211. 2007. View Article : Google Scholar : PubMed/NCBI
13	Chen KG and Sikic BI: Molecular pathways: regulation and therapeutic implications of multidrug resistance. Clin Cancer Res. 18:1863–1869. 2012. View Article : Google Scholar : PubMed/NCBI
14	Cheng GM and To KK: Adverse cell culture conditions mimicking the tumor microenvironment upregulate ABCG2 to mediate multidrug resistance and a more malignant phenotype. ISRN Oncol. 2012:7460252012. View Article : Google Scholar
15	Rohwer N and Cramer T: Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist Updat. 14:191–201. 2011. View Article : Google Scholar : PubMed/NCBI
16	Semenza GL: Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci. 33:207–214. 2012. View Article : Google Scholar : PubMed/NCBI
17	El Naggar A, Clarkson P, Zhang F, Mathers J, Tognon C and Sorensen PH: Expression and stability of hypoxia inducible factor 1α in osteosarcoma. Pediatr Blood Cancer. 59:1215–1222. 2012.
18	Ke Q and Costa M: Hypoxia-inducible factor-1 (HIF-1). Mol Pharmacol. 70:1469–1480. 2006. View Article : Google Scholar : PubMed/NCBI
19	Wang GL, Jiang BH, Rue EA and Semenza GL: Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O₂ tension. Proc Natl Acad Sci USA. 92:5510–5514. 1995. View Article : Google Scholar : PubMed/NCBI
20	Kallio PJ, Pongratz I, Gradin K, McGuire J and Poellinger L: Activation of hypoxia-inducible factor 1α: posttranscriptional regulation and conformational change by recruitment of the Arnt transcription factor. Proc Natl Acad Sci USA. 94:5667–5672. 1997.
21	Semenza GL: Hypoxia-inducible factor 1: master regulator of O₂ homeostasis. Curr Opin Genet Dev. 8:588–594. 1998. View Article : Google Scholar : PubMed/NCBI
22	Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC and Colgan SP: Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res. 62:3387–3394. 2002.PubMed/NCBI
23	Chen L, Feng P, Li S, Long D, Cheng J, Lu Y and Zhou D: Effect of hypoxia-inducible factor-1α silencing on the sensitivity of human brain glioma cells to doxorubicin and etoposide. Neurochem Res. 34:984–990. 2009.
24	Li J, Shi M, Cao Y, Yuan W, Pang T, Li B, Sun Z, Chen L and Zhao RC: Knockdown of hypoxia-inducible factor-1α in breast carcinoma MCF-7 cells results in reduced tumor growth and increased sensitivity to methotrexate. Biochem Biophys Res Commun. 342:1341–1351. 2006.
25	Liu L, Ning X, Sun L, Zhang H, Shi Y, Guo C, Han S, Liu J, Sun S, Han Z, Wu K and Fan D: Hypoxia-inducible factor-1 α contributes to hypoxia-induced chemoresistance in gastric cancer. Cancer Sci. 99:121–128. 2008.
26	Ding Z, Yang L, Xie X, Xie F, Pan F, Li J, He J and Liang H: Expression and significance of hypoxia-inducible factor-1 alpha and MDR1/P-glycoprotein in human colon carcinoma tissue and cells. J Cancer Res Clin Oncol. 136:1697–1707. 2010. View Article : Google Scholar : PubMed/NCBI
27	Chi SN, Conklin LS, Qin J, Meyers PA, Huvos AG, Healey JH and Gorlick R: The patterns of relapse in osteosarcoma: the Memorial Sloan-Kettering experience. Pediatr Blood Cancer. 42:46–51. 2004. View Article : Google Scholar : PubMed/NCBI
28	Chou AJ and Gorlick R: Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther. 6:1075–1085. 2006. View Article : Google Scholar : PubMed/NCBI
29	Saraswathy M and Gong S: Different strategies to overcome multidrug resistance in cancer. Biotechnol Adv. 31:1397–1407. 2013. View Article : Google Scholar : PubMed/NCBI
30	Gillet JP, Efferth T and Remacle J: Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim Biophys Acta. 1775:237–262. 2007.PubMed/NCBI
31	Yokochi T and Robertson KD: Doxorubicin inhibits DNMT1, resulting in conditional apoptosis. Mol Pharmacol. 66:1415–1420. 2004. View Article : Google Scholar : PubMed/NCBI
32	Wardman P: Electron transfer and oxidative stress as key factors in the design of drugs selectively active in hypoxia. Curr Med Chem. 8:739–761. 2001. View Article : Google Scholar : PubMed/NCBI
33	Weidemann A and Johnson RS: Biology of HIF-1α. Cell Death Differ. 15:621–627. 2008.
34	Grassilli E, Ballabeni A, Maellaro E, Del Bello B and Helin K: Loss of MYC confers resistance to doxorubicin-induced apoptosis by preventing the activation of multiple serine protease- and caspase-mediated pathways. J Biol Chem. 279:21318–21326. 2004. View Article : Google Scholar : PubMed/NCBI
35	Nakagawara A, Kadomatsu K, Sato S, Kohno K, Takano H, Akazawa K, Nose Y and Kuwano M: Inverse correlation between expression of multidrug resistance gene and N-myc oncogene in human neuroblastomas. Cancer Res. 50:3043–3047. 1990.PubMed/NCBI
36	Prados J, Melguizo C, Fernandez A, Aranega AE, Alvarez L and Aranega A: Inverse expression of mdr1 and c-myc genes in rhabdomyosarcoma cell line resistant to actinomycin d. J Pathol. 180:85–89. 1996.
37	Dang CV, Kim JW, Gao P and Yustein J: The interplay between MYC and HIF in cancer. Nat Rev Cancer. 8:51–56. 2008. View Article : Google Scholar : PubMed/NCBI
38	Yoo YG, Christensen J and Huang LE: HIF-1α confers aggressive malignant traits on human tumor cells independent of its canonical transcriptional function. Cancer Res. 71:1244–1252. 2011.
39	Hayashi M, Yoo YG, Christensen J and Huang LE: Requirement of evading apoptosis for HIF-1α-induced malignant progression in mouse cells. Cell Cycle. 10:2364–2372. 2011.PubMed/NCBI
40	Wanzel M, Herald S and Eilers M: Transcriptional repression by Myc. Trends Cell Biol. 13:146–150. 2003. View Article : Google Scholar : PubMed/NCBI
41	Herkert B and Eilers M: Transcriptional repression: the dark side of myc. Genes Cancer. 1:580–586. 2010. View Article : Google Scholar : PubMed/NCBI
42	Gorospe M, Wang X and Holbrook NJ: Functional role of p21 during the cellular response to stress. Gene Expr. 7:377–385. 1999.PubMed/NCBI
43	Li Y, Dowbenko D and Lasky LA: AKT/PKB phosphorylation of p21^Cip/WAF1 enhances protein stability of p21^Cip/WAF1 and promotes cell survival. J Biol Chem. 277:11352–11361. 2002.PubMed/NCBI
44	Barboule N, Chadebech P, Baldin V, Vidal S and Valette A: Involvement of p21 in mitotic exit after paclitaxel treatment in MCF-7 breast adenocarcinoma cell line. Oncogene. 15:2867–2875. 1997. View Article : Google Scholar : PubMed/NCBI
45	Zhang W, Kornblau SM, Kobayashi T, Gambel A, Claxton D and Deisseroth AB: High levels of constitutive WAF1/Cip1 protein are associated with chemoresistance in acute myelogenous leukaemia. Clin Cancer Res. 1:1051–1057. 1995.PubMed/NCBI
46	Erber R, Klein W, Andl T, Enders C, Born Al, Conradt C, Bartek J and Bosch FX: Aberrant p21^CIP1/WAF1 protein accumulation in head-and-neck cancer. Int J Cancer. 74:383–389. 1997.
47	Wang Y, Blandino G and Givol D: Induced p21^waf expression in H1299 cell line promotes cell senescence and protects against cytotoxic effect of radiation and doxorubicin. Oncogene. 18:2643–2649. 1999.
48	Haas-Kogan D, Shalev N, Wong M, Mills G, Yount G and Stokoe D: Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr Biol. 8:1195–1198. 1998. View Article : Google Scholar : PubMed/NCBI
49	Wang CC, Liao YP, Mischel PS, Iwamoto KS, Cacalano NA and McBride WH: HDJ-2 as a target for radiosensitization of glioblastoma multiforme cells by the farnesyltransferase inhibitor R115777 and the role of p53/p21 pathway. Cancer Res. 66:6756–6762. 2006. View Article : Google Scholar : PubMed/NCBI
50	Glaser T, Wagenknecht B and Weller M: Identification of p21 as a target of cycloheximide-mediated facilitation of CD95-mediated apoptosis in human malignant glioma cells. Oncogene. 20:4757–4767. 2001. View Article : Google Scholar
51	Happold C, Roth P, Wick W, Schmidt N, Florea AM, Silginer M, Reifenberger G and Weller M: Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells. J Neurochem. 122:444–455. 2012. View Article : Google Scholar : PubMed/NCBI